Details for New Drug Application (NDA): 202938
✉ Email this page to a colleague
The generic ingredient in HYDRALAZINE HYDROCHLORIDE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for 202938
| Tradename: | HYDRALAZINE HYDROCHLORIDE |
| Applicant: | Navinta Llc |
| Ingredient: | hydralazine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 202938
| Physiological Effect | Arteriolar Vasodilation |
Medical Subject Heading (MeSH) Categories for 202938
Suppliers and Packaging for NDA: 202938
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | INJECTABLE;INJECTION | 202938 | ANDA | Navinta LLC | 68475-514 | 68475-514-02 | 25 VIAL in 1 PACKAGE (68475-514-02) / 1 mL in 1 VIAL (68475-514-01) |
| HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride | INJECTABLE;INJECTION | 202938 | ANDA | Zydus Pharmaceuticals USA Inc. | 70710-1988 | 70710-1988-7 | 25 VIAL in 1 PACKAGE (70710-1988-7) / 1 mL in 1 VIAL (70710-1988-1) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/ML | ||||
| Approval Date: | Mar 28, 2013 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
